CPT code 83950 represents a laboratory assay that measures the HER2/neu oncoprotein in serum. The test is clinically relevant for monitoring patients with a prior breast cancer diagnosis, offering a minimally invasive method to track tumor marker levels over time. Nationally, HER2 monitoring supports oncologists in assessing disease progression or response to therapy and can inform follow-up care decisions.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service setting, plus what to expect in payer coverage discussions and common billing considerations. The publication outlines benchmarks and payment policy themes relevant to laboratory oncology testing, summarizes typical sites of service, and highlights where additional coding or documentation details may be required. This resource is intended to help billing professionals, laboratory managers, and clinical teams understand the role of CPT code 83950 in cancer monitoring workflows and payer interactions.

Data not available in the input for specific associated taxonomies, ICD-10 diagnoses, related codes, and detailed payer-specific reimbursement rates.